- Companies
- Thyme Care
Thyme Care Valuation, Funding & Investors
Thyme Care is valued at $2B as of September 2026.
Last Thyme Care valuation
$2B
Series E · Sep 2026
Last Thyme Care funding round
$125M
Series E · Sep 2026
Cumulative funding Thyme Care raised
$359M
across 5 funding rounds
Key investors in Thyme Care
Andreessen Horowitz
AlleyCorp
Frist Cressey Ventures
Foresite Capital
Town Hall Ventures
CVS Health Ventures
About Thyme Care
Thyme Care is a New York-based oncology care management company partnering with health plans to deliver integrated support for cancer patients. The platform coordinates navigation, symptom management, psychosocial care, and financial assistance across 20 US states. Thyme Care's clinicians collaborate with oncologists at over 100 provider sites, using data analytics to personalize care journeys for members of payers like Aetna and Cigna. Founded in 2020, the company has enrolled thousands of patients in its whole-person care model.
Founded
2020
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Services
Valuation
$2B (Sep 2026)
Thyme Care Valuation
Thyme Care is currently valued at $2B, based on its Series E in September 2026.
The $125M round was led by Morgan Health, with participation from HealthQuest Capital, Frist Cressey Ventures, Humana Inc., Concord Health Partners, Town Hall Ventures and 4 other investors.
Thyme Care's valuation has grown 11x from $181M at its Series B in August 2023 to $2B in September 2026, across 4 priced rounds.
Thyme Care valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Sep 2026 | Series E | $2B |
| Sep 2025 | Series D | $1B |
| Jul 2024 | Series C | $480M |
| Aug 2023 | Series B | $181M |
Thyme Care Funding History
Thyme Care has raised a total of $359M across 5 funding rounds.
Thyme Care's first fundraising round was a $22M Series A in October 2021. The most recent completed round was a $125M Series E in September 2026.
Thyme Care funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Sep 2026 | Series E | Morgan Health (lead); HealthQuest Capital; Frist Cressey Ventures; Humana Inc.; Concord Health Partners; Town Hall Ventures; Foresite Capital; Andreessen Horowitz; CVS Health Ventures; AlleyCorp | $125M | $2B | Thyme Care raised more than $125 million in a Series E financing led by Morgan Health in September 2026, with participation from Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures, and a16z Bio + Health. The round valued the oncology-focused company at more than $2 billion and accompanied the launch of a new parent organization, Thyme Companies, to broaden its footprint beyond cancer care navigation. The financing was positioned to support continued growth and expansion into a wider oncology ecosystem, building on Thyme Care’s existing care-navigation model and payer/provider partnerships. The company is based in Nashville and focuses on improving the patient experience for people undergoing cancer treatment while working with strategic healthcare investors and operators across the industry. Thyme Care had previously raised a $97 million Series D at a $1 billion valuation in 2025, and the new round roughly doubled that valuation. The company’s investor base includes both strategic healthcare backers and institutional venture firms, reflecting its role at the intersection of oncology care delivery, navigation, and value-based partnerships. |
| Sep 2025 | Series D | Frist Cressey Ventures; Humana Inc.; Concord Health Partners; Town Hall Ventures; Foresite Capital; Andreessen Horowitz; Texas Oncology Physicians Association; CVS Health Ventures; Morgan Health; Memorial Hermann Health System; AlleyCorp | $97M | $1B | Thyme Care is a value-based cancer care enabler founded in 2020 that collaborates with health plans, employers, and healthcare providers to transform oncology care delivery and outcomes. The company operates a hybrid collaborative care model combining a technology-enabled care team with seamless provider integration, working with more than 1,000 oncologists nationwide to reduce administrative burden, support higher-value drug choices, and integrate services such as palliative care and survivorship. In September 2025, Thyme Care raised $97 million in Series D funding backed by existing investors CVS Health Ventures, Foresite Capital, a16z Bio + Health, Concord Health Partners, Town Hall Ventures, AlleyCorp, and Frist Cressey Ventures, alongside new strategic investors Morgan Health (JPMorganChase's employer healthcare division), Humana, Texas Oncology, and Memorial Hermann Health System. The round valued the company at more than $1 billion, representing a 2x increase from its July 2024 valuation, and brought total capital raised to $275 million. By the time of the Series D announcement, Thyme Care had achieved profitability, grown from 10,000 patients in late 2024 to 80,000 active patients, and expanded access to 8 million people nationwide through Medicare, commercial, and employer contracts. The company manages more than $5 billion in oncology spend annually, with data demonstrating measurable clinical and financial impact: its navigation services reduce emergency room visits by 40% and hospital admissions by 19%. CEO Robin Shah indicated the company would use new funding to expand across additional verticals, tackle key pain points in the oncology journey including treatment denials and high drug costs, accelerate AI platform development, and build enhanced member-facing applications and care team tools. |
| Jul 2024 | Series C | Concord Health Partners (lead); Frist Cressey Ventures; Town Hall Ventures; Foresite Capital; Andreessen Horowitz; CVS Health Ventures; Echo Health Ventures; AlleyCorp | $55M | $480M | Thyme Care is a Nashville-based value-based cancer care navigation company founded in 2020 that partners with payers, employers, and providers to reduce costs and improve patient outcomes across the cancer care continuum. The company combines 24/7 cancer care navigation, technology-driven data insights, and oncologist-led interventions, engaging more than 1,000 oncologists through its Thyme Care Oncology Partners network and assuming two-sided financial risk to align incentives. In July 2024, Thyme Care closed a $95 million Series C funding round with $55 million in equity funding, welcoming new investor Concord Health Partners and participation from existing investors including CVS Health Ventures, Town Hall Ventures, a16z Bio + Health, AlleyCorp, Echo Health Ventures, Frist Cressey Ventures, and Foresite Capital. The round valued the company at $480 million post-money. Banc of California provided an additional $40 million in debt financing. The company used proceeds to expand into new geographies, build partnerships with oncologists, primary care practices and health plans, and deepen its clinical value-based care model. At the time of the Series C round, Thyme Care was actively managing more than half a billion dollars in medical spend across risk-based contracts and was on pace to more than triple that number within the following year. The company had more than doubled its oncology partnerships over the prior six months and was serving approximately 3,000 patients and families navigating cancer and serious illness through contracts with risk-bearing entities. The company had raised $178 million cumulatively before the Series C, including a $60 million Series B raised in October 2023. By September 2025, Thyme Care achieved unicorn status, raising $97 million in a Series D round that doubled its valuation from the July 2024 level to more than $1 billion. The company had scaled to 80,000 active patients, become profitable, and was managing more than $5 billion in oncology spend. Its services were accessible to 8 million people through Medicare, commercial, and employer contracts with national partnerships including Aetna, Humana, and Fortune 500 employers. |
| Aug 2023 | Series B | Foresite Capital (lead); Town Hall Ventures (lead); Frist Cressey Ventures; Casdin Capital; Andreessen Horowitz; AlleyCorp | $60M | $181M | Thyme Care is a value-based cancer care platform that partners with oncologists, payers, employers, and providers to deliver comprehensive support for cancer patients, including tech-enabled care management, symptom management, behavioral health resources, housing, transportation, and financial assistance. Founded in 2020 by oncology veterans like CEO Robin Shah, Bobby Green MD, and Brad Diephuis MD, the company aims to streamline fragmented oncology care, reduce administrative burdens, promote higher-value treatments, and shift toward proactive, patient-centered models. It rewards oncologists for clinical and cost savings performance through value-based contracts with payers and risk-bearing primary care providers. On August 22, 2023, Thyme Care announced a $60 million Series B funding round co-led by Town Hall Ventures and Foresite Capital, with participation from Andreessen Horowitz Bio + Health, AlleyCorp, Casdin Capital, and Frist Cressey Ventures, bringing total capital raised to over $80 million. The funds were earmarked for geographic expansion of its national network of oncology partners and enhancement of cancer care support services. David Whelan from Town Hall Ventures and Elizabeth Canis from Foresite Capital joined the board. Subsequent developments include later rounds: a $95 million raise in July 2024 and a $97 million Series D in 2025 backed by CVS Health Ventures, Humana, Morgan Health, Texas Oncology, Memorial Hermann, and existing investors, pushing total funding to $275 million and valuation north of $1 billion, with the company achieving profitability and managing over $5 billion in oncology spend for 8 million lives. |
| Oct 2021 | Series A | AlleyCorp (lead); Andreessen Horowitz (lead); Frist Cressey Ventures (lead); Puneet Singh; Casdin Capital; Bessemer Venture Partners; Vivek Garipalli | $22M | - | Thyme Care, a Nashville-based oncology care management startup founded in 2020, closed a $22 million funding round on or around October 4-5, 2021, led by Andreessen Horowitz, AlleyCorp, and Frist Cressey Ventures, with participation from Casdin Capital, Bessemer Venture Partners, Puneet Singh, and Vivek Garipalli. The company provides high-touch, tech-enabled cancer care navigation services, partnering with health plans, employers, and oncologists to close care gaps, reduce unnecessary spending, and improve patient outcomes through its platform that connects patients, caregivers, payers, and clinicians while using data for early identification. The funding was intended to accelerate development of Thyme Care's technology platform and expand partnerships with oncologists, health plans, employers, and risk-based entities. CEO Robin Shah, an oncology veteran, emphasized the platform's role in providing insider-like support throughout the cancer journey, addressing disparities in patient experiences. The company had recently announced a collaboration with Clover Health to offer personalized cancer support to Medicare Advantage members in New Jersey at no cost. Later rounds included a $60M Series B led by Town Hall Ventures and Foresite Capital (with prior investors participating), bringing total funding over $80M, and a $97M Series D in 2024 that valued the company above $1B (up from $480M previously), backed by CVS Health Ventures, Humana, Morgan Health, and Memorial Hermann, signaling strong growth in value-based cancer care. |
Who has invested in Thyme Care?
17 investors have backed Thyme Care across its funding rounds, including Andreessen Horowitz, AlleyCorp, Frist Cressey Ventures, Foresite Capital, Town Hall Ventures and CVS Health Ventures.
Lead investors include Morgan Health, Concord Health Partners, Foresite Capital, Town Hall Ventures, AlleyCorp and 2 other investors.
Thyme Care Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 5 | Lead | Oct 2021 | ||
| 5 | Lead | Oct 2021 | ||
| 5 | Lead | Oct 2021 | ||
| 4 | Lead | Aug 2023 | ||
| 4 | Lead | Aug 2023 | ||
| 3 | Lead | Jul 2024 | ||
| 3 | Participant | Jul 2024 | ||
| 2 | Participant | Sep 2025 | ||
| 2 | Participant | Oct 2021 | ||
| 2 | Lead | Sep 2025 | ||
| 1 | Participant | Sep 2026 | ||
| 1 | Participant | Oct 2021 | ||
| 1 | Participant | Oct 2021 | ||
This data is available for Pro users. Sign up to see all 17 Thyme Care investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialThyme Care Competitors
Thyme Care competitors include listed companies like Clover Health and Molina Healthcare, and private ones like Main Street Health, Garner Health, MediTrust Health and Grand Rounds.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $1.9B | ($84M) | $2.4B | 0.8x | ||
| Private | - | - | $1.5B | - | ||
| Private | $200M | - | $2.7B | 13.7x | ||
| Private | $154M | - | $1.4B | 9.3x | ||
| Private | - | - | $1.3B | - | ||
| Publicly listed | $45B | $976M | $11B | 0.1x |
Thyme Care Public Comps
Thyme Care is still privately-owned, but its public comps include Progyny, Alignment Healthcare, Pluxee, Clover Health, GoodRx, Eurowag, Hapvida, Evolent Health, Value HR and MetropolCard.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $1.3B | $90M | 1.4x | 1.4x | 20.6x | 8.0x | |||
| $3.9B | $45M | 0.4x | 0.3x | 31.6x | 10.0x | |||
| $1.5B | $500M | - | - | - | - | |||
| $1.9B | ($84M) | 1.1x | 0.8x | (25.8x) | 34.1x | |||
| $797M | $173M | 1.8x | 1.8x | 8.1x | 5.5x | |||
| $2.7B | $119M | 0.5x | 3.0x | 10.3x | 7.5x | |||
| $6.1B | $787M | 0.3x | 0.3x | 2.7x | 4.0x | |||
| $1.9B | ($365M) | 0.7x | 0.5x | (3.5x) | 9.4x | |||
This data is available for Pro users. Sign up to see all Thyme Care competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Thyme Care
| When was Thyme Care founded? | Thyme Care was founded in 2020. |
| Where is Thyme Care headquartered? | Thyme Care is headquartered in Nashville, TN, United States. |
| Is Thyme Care publicly listed? | No, Thyme Care is a private, VC-backed company. |
| What is Thyme Care's valuation? | Thyme Care was last valued at $2B in its Series E in September 2026. |
| How much funding has Thyme Care raised? | Thyme Care has raised $359M across 5 funding rounds. |
| What was Thyme Care's last funding round? | Thyme Care's last funding round was a $125M Series E in September 2026, led by Morgan Health. |
| Who are Thyme Care's investors? | Thyme Care's investors include Frist Cressey Ventures, Andreessen Horowitz, AlleyCorp, Town Hall Ventures, Foresite Capital, Concord Health Partners, CVS Health Ventures, Humana Inc., Casdin Capital, Morgan Health and 7 others. |
| Which companies are comparable to Thyme Care? | Companies comparable to Thyme Care include Clover Health, Main Street Health, Garner Health, MediTrust Health, Grand Rounds and Molina Healthcare. |
See companies similar to Thyme Care
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




